Abraxis BioScience, Inc. Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (ABRAXANE(R)) with Anti-Angiogenic Agents to Increase Tumor Response

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, discussed results from two pre-clinical studies that provide evidence for chemotherapy induced angiogenesis and rationale for combining nab-paclitaxel (ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)) with VEGF inhibitor drugs like bevacizumab (Avastin®) at the 98th American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2007 in Los Angeles.